Table 4.
Summary of the clinical trials of vaccines for treatment of COVID-19.
| Sr. no | Vaccine intervention/treatment | Sponsor | Clinical phase (sample size) |
Status | Clinical trial identifier |
|---|---|---|---|---|---|
| 1. | INO-4800, a Prophylactic Vaccine; Intradermally | Inovio Pharmaceuticals, USA | Phase I (40) |
On-going | NCT04336410 |
| 2. | 2019-nCoV Vaccine (mRNA-1273) Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV |
National Institute of Allergy and Infectious Diseases (NIAID), USA | Phase I (45) |
Completed | NCT04283461 |
| 3. | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | Moderna TX, Inc. | Phase II (600) |
On-going | NCT04405076 |
| 4. | Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates (BNT162a1, BNT162b1, BNT162b2 and BNT162c2) against COVID-19 in Healthy Adults | Biontech SE Pfizer |
Phase I (7600) |
Completed | NCT04368728 |
| 5. | A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults | Biontech RNA Pharmaceuticals GmbH | Phase1 &II (200) |
On-going | NCT04380701 |
| 6. | Pathogen-specific aAPC; Subcutaneously | Shenzhen Geno-Immune Medical Institute, Guangdong, China | Phase I (100) |
On-going | NCT04299724 |
| 7. | Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus; Subcutaneously | Shenzhen Geno-Immune Medical Institute, Guangdong, China | Phase I &II (100) |
On-going | NCT04276896 |
| 8. | BCG Vaccine for Covid-19; Intracutaneously | UMC Utrecht, Netherland | Phase III (1500) |
On-going | NCT04328441 |
| 9. | SARS-CoV-2 Inactivated Vaccine | Sinovac Biotech Co., Ltd., Jiangsu, China | Phase I (Medium Dose, 144) Phase II (High Dose, 600) |
On-going | NCT04352608 |
| 10. | BCG Vaccine for Covid-19; Intradermally | Murdoch Children's Research Institute, Victoria, Australia |
Phase III (4170) |
On-going | NCT04327206 |
| 11. | Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |
University of Oxford, United Kingdom | Phase I & II (1090) |
Completed | NCT04324606 |
| 12. | Investigating a Vaccine Against COVID-19 | University of Oxford, United Kingdom | Phase II & III (10260) |
On-going | NCT04400838 |
| 13. | Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | CanSino Biologics Inc. | Phase I (108) |
Completed | NCT04313127 |
| 14. | A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV) | CanSino Biologics Inc. Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
Phase II (508) |
On-going | NCT04341389 |
| 15. | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant | Novavax | Phase I (131) |
On-going | NCT04368988 |
| 16. | Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) | Sinovac Research and Development Co., Ltd. | Phase I (72) Phase II (350) |
On-going | NCT04383574 |